2009
DOI: 10.1134/s1990519x09050083
|View full text |Cite
|
Sign up to set email alerts
|

Analysis of tyrphostin AG1478 effect on behavior of internalized EGF receptor at different stages of endocytosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…Similarly, it has been demonstrated that PD158780, another EGF receptor tyrosine kinase inhibitor, also affected early steps of internalization [Sorkina et al, 2002;Wolf et al, 2011]. Thus, it is possible that these inhibitors may work at different steps during endocytosis of EGF-receptor by affecting the recruitment of selective factors [Thomas et al, 2003;Kondratov et al, 2010]. PD158780 prevented the targeting of EGF-receptor into coated pits by altering the recruitment of subunits of the AP2 complex [Sorkina et al, 2002].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Similarly, it has been demonstrated that PD158780, another EGF receptor tyrosine kinase inhibitor, also affected early steps of internalization [Sorkina et al, 2002;Wolf et al, 2011]. Thus, it is possible that these inhibitors may work at different steps during endocytosis of EGF-receptor by affecting the recruitment of selective factors [Thomas et al, 2003;Kondratov et al, 2010]. PD158780 prevented the targeting of EGF-receptor into coated pits by altering the recruitment of subunits of the AP2 complex [Sorkina et al, 2002].…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, we raised the question of whether tyrosine kinase activity of the EGF-receptor is also required in the fusion between endosomes. To investigate this requirement, we first examined the effect of AG1478 inhibitor [Yamamoto et al, 2006;Kondratov et al, 2010] on the fusion reaction. As a control, we also examined the effect of an inactive tyrosine kinase inhibitor (AG9).…”
Section: Egf-receptor Tyrosine Kinase Inhibitor Inhibits In Vitro Endmentioning
confidence: 99%